Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Agios Pharmaceuticals Inc.

www.agiospharmaceuticals.com

Latest From ACS Dobfar SPA

Drug Recalls Soared Again in 2013, Driven by Contamination

FDA reported 1,276 drug recalls last year, the third-highest level ever. Inspections of pharmacies that compounded purportedly aseptic injectables drove the numbers, but pharmaceutical manufacturers also contributed as they struggled with particulates, precipitation and other issues.

BioPharmaceutical Recalls

Drug Recalls Soared Again in 2013, Driven by Contamination

FDA reported 1,276 drug recalls last year, the third-highest level ever. Inspections of pharmacies that compounded purportedly aseptic injectables drove the numbers, but pharmaceutical manufacturers also contributed as they struggled with particulates, precipitation and other issues.

Manufacturing Quality

Pharming: Back from the Brink of Bankruptcy

Two years ago it looked as if all was lost at Pharming: escalating costs for its Pompe's disease program and indebtedness to its JV partner Genzyme forced it into legal moratorium in August 2001. Today, Pharming's back in the game; indeed, its new management, slimmed down operations and heightened focus on cost control mirrors the many other European biotechs trying to adapt to the harsh winter. But Pharming could have avoided near death by not turning its development partner into its biggest creditor. Still, the firm's turnaround-even this far-shows a reassuring willingness among Europe's investors to assume risk and give companies another chance.
BioPharmaceutical Europe

Cubist: The Virtues of Pipeline Diversification

Cubist, like other companies in the anti-infectives space, was founded on the assumption that anti-infective drugs entering the clinic had a significantly lower risk of failure than other therapeutics. That risk profile may be changing because of the FDA's imposition of stricter standards for the approval of anti-microbials. So far, Cubist has met that challenge with respect to daptomycin, the Phase III antibiotic that would be the company's first marketed product. Yet, a cloud of regulatory uncertainty still lingers. But through aggressive dealmaking, Cubist has built a discovery and development pipeline that helps to balance the risk that daptomycin may run into unexpected roadblocks on the way to approval.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Agios Pharmaceuticals Inc.
  • Senior Management
  • David Schenkein, MD, CEO
    Andrew Hirsch, CFO
    Scott Biller, PhD, CSO
    John Evans, SVP, Corp. Dev. & Portfolio Leadership
  • Contact Info
  • Agios Pharmaceuticals Inc.
    Phone: (617) 649-8600
    88 Sidney St.
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register